Philadelphia, PA (May 16, 2018) – Oncoceutics, Inc. announced today its support for legislation that will increase awareness for diffuse intrinsic pontine glioma (DIPG), the most devastating type of brain cancer in children. Oncoceutics supports the efforts of the Jack’s Angels Foundation and Rep. Stephen Knight (CA) to pass H.Res.69 to designate May 17th as
Philadelphia, PA (April 16, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase I/II clinical trial of ONC201 in combination with ixazomib and dexamethasone in relapsed and/or refractory multiple myeloma. The trial, led by Ajai Chari, MD, Associate Professor at the Icahn School of Medicine at Mount Sinai,
Philadelphia, PA (April 5, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for patients with certain types of advanced endometrial and breast cancer. The Phase II trial is led by Alexandra Zimmer, MD, Assistant Research Physician at the Women’s Malignancies Branch at the National
Philadelphia, PA (March 19, 2018) – Oncoceutics, Inc. announced that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2018 annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois, on April 14th to April 18th. These abstracts highlight the unique way that ONC201 engages the
Business Development